Key Highlights
• Tenax Therapeutics and Orion Corporation finalized a supply agreement for levosimendan, with provisions for renewals.
• The deal extends the U.S. Regulatory approval deadline for levosimendan to December 31, 2035.
• Orion will serve as Tenax’s primary supplier for development and potential commercialization of the oral product.
• Both agreements include cost-sharing provisions for scaling Orion’s manufacturing capacity.
Tenax Therapeutics (NASDAQ: TENX) has strengthened its partnership with Orion Corporation, securing a long-term supply deal for levosimendan while extending a critical regulatory deadline. The agreements solidify Orion’s role as the primary manufacturer for Tenax’s oral levosimendan product, a potential treatment for pulmonary hypertension and heart failure.
Supply Agreement Terms
The newly signed supply agreement governs Orion’s production and delivery of levosimendan for Tenax. It establishes forecasting, pricing, and quality control protocols, with an initial term commencing with the first product delivery. The contract includes provisions for renewal after the initial period, which enables continued supply and collaboration.
Manufacturing and Cost Sharing
Orion will scale its manufacturing capabilities under the deal, with Tenax contributing to the expansion costs. The agreement also outlines procedures for handling any discrepancies related to product quality and grants Tenax alternative manufacturing rights if necessary.
Regulatory Deadline Extension
In a separate amendment, Tenax and Orion extended the U.S. Regulatory approval deadline for levosimendan to December 31, 2035. The original license agreement, first established in 2013, had undergone multiple revisions, with the latest amendment signed on June 29, 2026.
Cybersecurity and Compliance
The updated license agreement now requires Tenax to meet Orion’s information security and cybersecurity standards. All other terms of the original agreement remain unchanged, including intellectual property rights and milestone obligations.
Termination Clauses
The supply agreement includes provisions for termination in the event of significant violations or insolvency, ensuring both parties maintain accountability. Additionally, termination of the license agreement would also void the supply deal.
Strategic Implications
The agreements provide Tenax with a stable supply chain for levosimendan while extending its runway to secure FDA approval. Orion’s established manufacturing infrastructure could accelerate commercialization if the drug gains regulatory clearance.
Next Steps for Investors
Tenax plans to file the full supply agreement and sixth amendment as exhibits in its upcoming quarterly report. The company’s stock has seen volatility amid clinical development updates, and the extended timeline may ease investor concerns over regulatory hurdles.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...